Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1 year price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 175.7% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

Amneal Pharmaceuticals' stock was trading at $1.99 at the beginning of 2023. Since then, AMRX stock has decreased by 33.2% and is now trading at $1.33.
View the best growth stocks for 2023 here.

Amneal Pharmaceuticals saw a decline in short interest in February. As of February 28th, there was short interest totaling 7,120,000 shares, a decline of 11.7% from the February 13th total of 8,060,000 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is currently 5.5 days. Approximately 7.2% of the shares of the company are sold short.
View Amneal Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our AMRX earnings forecast.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) posted its quarterly earnings data on Thursday, March, 2nd. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.19 by $0.02. The firm had revenue of $609.80 million for the quarter, compared to the consensus estimate of $579.93 million. Amneal Pharmaceuticals had a negative net margin of 5.88% and a positive trailing twelve-month return on equity of 76.11%. The firm's quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the company earned $0.16 EPS.

Amneal Pharmaceuticals issued an update on its FY23 earnings guidance on Thursday, March, 2nd. The company provided EPS guidance of $0.40-0.50 for the period, compared to the consensus earnings per share estimate of $0.77. The company issued revenue guidance of $2.25-2.35 billion, compared to the consensus revenue estimate of $2.31 billion.

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Amneal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.65%), Morgan Stanley (1.39%), Norges Bank (0.89%), AQR Capital Management LLC (0.70%), Geode Capital Management LLC (0.60%) and Allspring Global Investments Holdings LLC (0.52%). Insiders that own company stock include Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends.

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRX stock can currently be purchased for approximately $1.33.

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $403.81 million and generates $2.21 billion in revenue each year. The company earns $-129,990,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

The company employs 7,600 workers across the globe.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.